Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

SCYNEXIS (SCYX) Stock Price & Analysis

1,577 Followers

SCYX Stock Chart & Stats

$3.21-$0.12(-3.60%)
At close: 4:00 PM EST
$4$5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$3.10 - $3.35
52-Week Range
$3.10 - $9.12
Previous Close
$3.33
Volume
N/A
Average Volume (3M)
92.78K
Market Cap
$33.14M
Enterprise Value
$13.02M
Total Cash (Recent Filing)
$47.16M
Total Debt (Recent Filing)
$1.82M
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
-0.63
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Non-dilutive Pipeline Funding

The BARDA cost-share contract can fund SCY-247 development through Phase 2 and potentially regulatory submissions while limiting reliance on shareholder dilution. It also supports progress in invasive candidiasis and reinforces SCYNEXIS’s position in drug-resistant fungal infections.

Strong Product Economics

Gross margins near 100% indicate that the underlying product economics can be attractive when commercial or licensing revenue is generated. This provides a favorable foundation for future operating leverage, although stronger sales are still needed to convert that margin potential into sustained profitability.

De-risked Leverage

The sharp reduction in leverage has materially improved financial flexibility compared with 2022, when debt was very high relative to thin equity. A low-debt structure reduces balance-sheet pressure and gives management more capacity to direct resources toward pipeline development and commercialization.

Bears Say

Revenue Contraction

The steep TTM revenue decline shows that commercial and licensing income remains highly unstable, limiting visibility into the company’s recurring revenue base. Persistent top-line weakness can delay operating leverage, reduce internal funding capacity, and make future performance more dependent on pipeline milestones.

Persistent Operating Losses

Ongoing net losses indicate that SCYNEXIS has not yet established durable profitability despite the strong gross-margin profile. Continued unprofitability can constrain strategic flexibility, require further financing or partnership support, and make earnings power highly dependent on successful product adoption.

Sustained Cash Burn

Negative operating and free cash flow demonstrate that the current business is consuming cash rather than funding its own development. If this run-rate persists, resources available for clinical programs and commercialization may tighten, increasing dependence on external funding or milestone-related receipts.

SCYNEXIS News

SCYX FAQ

What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $3.10 and its highest was $9.12 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $33.14M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 136 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Nov 05, 2026. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.72 by $0.01.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.63.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,953,155 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.72. Following the earnings report the stock price went down -14.063%.
Which hedge fund is a major shareholder of SCYNEXIS?
Hedge funds hold SCYNEXIS shares: the largest hedge-fund position in SCYNEXIS is 70,130,729 shares, and hedge funds increased their holdings by 387.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology